Japanese researchers restore sight with stem-cell cornea transplants in a world first

For the first time anywhere in the world, surgeons in Japan have used reprogrammed stem cells to repair damaged corneas — and for three of the four patients who received the transplants, the results have lasted more than a year. The trial marks a significant step forward in the effort to treat corneal blindness without relying on donor tissue.

At a glance

• Stem-cell cornea transplant: Four patients with severely impaired vision received transplants made from reprogrammed induced pluripotent stem cells (iPSCs) to replace damaged corneal tissue.
• Vision restored: Three of the four patients experienced substantial, lasting improvements in sight that persisted for more than a year after the procedure.
• World first: This is the first clinical use of iPSC-derived corneal cells to treat humans, with results published in The Lancet in 2024 C.E.

What the surgery involved

The cornea is the clear outer layer of the eye that focuses incoming light. When it’s damaged by disease or injury, vision can deteriorate severely — and in many cases, the only existing treatment is a transplant of donor corneal tissue. But donor tissue is in short supply globally, and recipients face the risk of rejection.

The Japanese research team, whose findings were published in The Lancet in 2024 C.E., took a different route. They used induced pluripotent stem cells — adult cells that have been chemically “reprogrammed” back into an earlier, more flexible state — and guided them to become corneal epithelial cells. These were then formed into thin sheets and transplanted onto the patients’ eyes.

The procedure bypasses the donor shortage problem entirely. iPSCs can, in theory, be produced in large quantities from a relatively small number of donor cell lines.

Why the results matter

Three of the four patients saw meaningful, sustained improvements in their vision over more than 12 months of follow-up. The fourth patient also gained ground initially, but those gains did not hold. Researchers are studying why the outcomes differed.

Even so, a 75% sustained success rate in a first-in-human trial is a notable early result. The World Health Organization estimates that corneal conditions are among the leading causes of blindness worldwide, affecting tens of millions of people — with the burden falling disproportionately on lower-income countries where donor tissue and surgical infrastructure are least available.

If the approach can be scaled and made affordable, it could eventually reach patients who currently have no viable treatment options.

A growing frontier in regenerative medicine

This trial sits within a rapidly expanding body of work using iPSCs to repair or replace damaged human tissue. Japanese researchers have been at the forefront of this field since Shinya Yamanaka won the Nobel Prize in Physiology or Medicine in 2012 C.E. for discovering how to create iPSCs. Earlier trials in Japan have tested similar reprogrammed cells in patients with Parkinson’s disease and heart conditions.

The cornea is actually a relatively favorable target for this kind of therapy. It’s accessible, it can be monitored closely after surgery, and the immune environment of the eye is less aggressive than in other parts of the body — which reduces the risk of rejection. That makes it a useful proving ground for techniques that researchers hope to eventually apply more broadly.

RIKEN, Japan’s national research institute, has been central to the iPSC research program behind this work.

What still needs to happen

This was a small, early-phase trial. Before stem-cell cornea transplants can become a standard treatment, researchers will need to run larger trials, confirm long-term safety, and understand why outcomes varied between patients. The cost of producing iPSC-derived tissue at scale also remains a significant challenge — one that will need to be solved if this approach is ever to be widely accessible rather than available only in well-funded research hospitals.

Still, what’s happened here is rare: a genuine first. Four people received something no one had received before, and most of them can see more clearly because of it.

Read more

For more on this story, see: Nature

For more from Good News for Humankind, see:

• Renewables now make up at least 49% of global power capacity
• U.K. cancer death rates down to their lowest level on record
• The Good News for Humankind archive on global health

About this article

• 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
• 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
• 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
• ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.